RE:RE:RE:“Second mouse gets the cheese “For those who can't see the larger picture BioNTech / Genentech's Phase 2 mRNA "vaccine" clinical trial involving adjuvant autogene cevumeran in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy compared with the current standard of care chemotherapy (mFOLFIRINOX) in patients in resected PDAC, this BioNTech study is an "open-label" study rather than a randomized study (which is the kind of clinical study the FDA has signalled as preferable). In addition the Phase 2 BioNTech mRNA "vaccine" study does not employ "biomarkers" or validated "surrogate endpoints" such as ORR, PFS or mOS as primary endpoints, BioNTech / Genentech's Phase 2 mRNA "vaccine" study is measuring disease-free survival as the primary endpoint, which is not as rigourous as ORR, PFS or mOS, which ONCY's Goblet-1 metastatic PDAC study has employed
https://clinicaltrials.gov/study/NCT05968326